Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Fig. 1

HER3 immunohistochemistry. a Positive control (prostate), b Concurrently high (score 3+) membranous and cytoplasmic HER3 expression (breast carcinoma), c High (score 3+) membranous HER3 expression with negative/low (score 0) cytoplasmic HER3 status, d Negative/low total cellular HER3 staining. Mayer's Hematoxylin used as a counterstain

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us